U.S. Markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.5418%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.4601%)
     
  • BTC-USD

    60,667.80
    +192.09 (+0.32%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300 American medical institutions.

  • The treatment is already being administered to some patients, the head of Eisai's neurology business told Nikkei.

  • Aducanumab received conditional approval from the FDA in June under a cloud of doubts.

  • The drug targets plaques in the brain formed by amyloid proteins believed to be a significant cause of Alzheimer's-related dementia.

  • Eisai has identified around 900 U.S. medical centers seen as likely to adopt the treatment.

  • How many patients actually receive the expensive drug is being closely watched to indicate whether it will reach blockbuster status.

  • Some medical centers, including Mount Sinai Health System and Cleveland Clinic, have chosen not to use Aduhelm.

  • Eisai says that medical institutions that initially took a pass on the drug could introduce it later.

  • Price Action: BIIB shares are up 0.68% at $345.83, while ESALY shares are down 0.33% at $82.48 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.